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Objectives This study sought to compare the clinical outcomes of everolimus-eluting stents (EES)
versus paclitaxel-eluting stents (PES) in patients with acute coronary syndromes (ACS) and stable
coronary artery disease (CAD).
Background Although randomized trials have shown superiority of EES to PES, the safety and efﬁ-
cacy of EES in ACS is unknown.
Methods We performed a patient-level pooled analysis from the prospective, randomized SPIRIT (Clinical
Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) II, III, IV, and COMPARE (A Trial of
Everolimus-Eluting Stents and Paclitaxel-Eluting Stents for Coronary Revascularization in Daily Practice) trials in
which 2,381 patients with ACS and 4,404 patients with stable CAD were randomized to EES or to PES. Kaplan-
Meier estimates of death, myocardial infarction (MI), ischemia-driven target lesion revascularization, and stent
thrombosis were assessed at 2 years and stratiﬁed by clinical presentation (ACS vs. stable CAD).
Results At 2 years, patients with ACS compared with stable CAD had higher rates of death (3.2% vs.
2.4%, hazard ratio [HR]: 1.37 [95% conﬁdence interval (CI): 1.02 to 1.85], p  0.04) and MI (4.9% vs. 3.4%,
HR: 1.45 [95% CI: 1.14 to 1.85], p  0.02). In patients with ACS, EES versus PES reduced the rate of death
or MI (6.6% vs. 9.3%, HR: 0.70 [95% CI: 0.52 to 0.94], p  0.02), stent thrombosis (0.7% vs. 2.9%, HR: 0.25
[95% CI: 0.12 to 0.52], p  0.0002), and ischemia-driven target lesion revascularization (4.7% vs. 6.2%,
HR: 0.69 [95% CI: 0.48 to 0.99], p  0.04). In patients with stable CAD, EES reduced the rate of death or
MI (4.5% vs. 7.1%, HR: 0.62 [95% CI: 0.48 to 0.80], p  0.0002), stent thrombosis (0.7% vs. 1.8%, HR: 0.34
[95% CI: 0.19 to 0.62], p  0.0002), and ischemia-driven target lesion revascularization (3.9% vs. 6.9%,
HR: 0.55 [95% CI: 0.42 to 0.73], p  0.0001).
Conclusions Treatment with EES versus PES provides enhanced safety and efﬁcacy regardless of the acuity
of the clinical syndrome being treated and appears to mitigate the increased risk of stent thrombosis associ-
ated with ACS. (A Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treat-
ment of Patients With de Novo Native Coronary Artery Lesions [SPIRIT II]; NCT00180310; SPIRIT III: A Clinical
Evaluation of the Investigational Device XIENCE V Everolimus Eluting Coronary Stent System [EECSS] in the
Treatment of Subjects With de Novo Native Coronary Artery Lesions [SPIRIT III]; NCT00180479; SPIRIT IV Clinical
Trial: Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Sub-
jects With de Novo Native Coronary Artery Lesions [SPIRIT IV]; NCT00307047; A Trial of Everolimus-Eluting
Stents and Paclitaxel-Eluting Stents for Coronary Revascularization in Daily Practice: the COMPARE Trial
[COMPARE]; NCT01016041) (J Am Coll Cardiol Intv 2011;4:1104–15) © 2011 by the American College of
Cardiology Foundation
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1105Drug-eluting stents (DES) substantially reduce angio-
graphic restenosis and the clinical need for repeat revascu-
larization procedures (1,2). Nevertheless, despite some evi-
dence of their safety in patients with acute coronary
syndromes (ACS) (3–5), the routine use of DES in ACS
remains controversial (6–8). Furthermore, there are no
randomized studies comparing different types of DES in
ACS patients.
See page 1116
Second-generation DES were designed in part to
address lingering concerns regarding DES safety and
late stent thrombosis, especially in high-risk patients. In
the everolimus-eluting stent(s) (EES), the antiprolifera-
tive agent everolimus, a rapamycin analog, is released
from a thin, biocompatible fluorocopolymer that is de-
ployed on a low-profile (81-m strut thickness), flexible
cobalt chromium stent (9). In the paclitaxel-eluting
stent(s) (PES), paclitaxel is released from a styrene-
isoprene-butadiene-styrene copolymer, deployed on a
stainless steel stent with 132- or 97-m strut thickness (Taxus
xpress2 and Taxus Liberté, respectively, Boston Scientific,
atick, Massachusetts) (10,11).
Several randomized trials and real-world registries have
hown superior safety and efficacy of EES versus a commonly
sed PES (9,12–16). However, these studies were underpow-
red for subgroup analysis of high-risk patients with ACS,
specially for the detection of differences in uncommon
vents, such as stent thrombosis. Consequently, the relative
afety and efficacy of EES in patients with ACS has not
een established. Therefore, we sought to compare the
linical outcomes of EES versus PES in patients with ACS
nd stable coronary artery disease (CAD). To achieve
ufficient power to address this question, we performed a
atient-level pooled analysis from the 4 completed random-
zed trials comparing EES with PES.
ethods
Patient population and study procedure. We combined the
databases from the SPIRIT II (A Clinical Evaluation of the
XIENCE V Everolimus Eluting Coronary Stent System in
the Treatment of Patients With de Novo Native Coronary
Artery Lesions), SPIRIT III (A Clinical Evaluation of the
From the *Columbia University, Medical Center and the Cardiovascular Research
Foundation, New York, New York; †Christ Hospital Heart and Vascular Center and The
Carl and Edyth Lindner Center for Research and Education, Cincinnati, Ohio;
‡Department of Cardiology, Maasstad Ziekenhuis, Rotterdam, the Netherlands; and the
§Thoraxcenter, Erasmus Medical Center, Rotterdam, the Netherlands. The SPIRIT
trials were sponsored and funded by Abbott Vascular. The COMPARE trial was
sponsored by the Department of Cardiology, Maasstad Ziekenhuis and funded by
unrestricted research grants from Abbott Vascular and Boston Scientific. The present
study was supported in part by a grant from Abbott Vascular. Dr. Smits has served as aInvestigational Device XIENCE V Everolimus Eluting
Coronary Stent System (EECSS) in the Treatment of
Subjects With de Novo Native Coronary Artery Lesions),
SPIRIT IV (Clinical Evaluation of the XIENCE V
Everolimus Eluting Coronary Stent System in the Treat-
ment of Subjects With de Novo Native Coronary Artery
Lesions), and COMPARE (A Trial of Everolimus-Eluting
Stents and Paclitaxel-Eluting Stents for Coronary Revascu-
larization in Daily Practice) trials. The protocol and prin-
cipal results of each trial have been published elsewhere
(12,13,15,17). The major characteristics of each trial are
presented in Table 1. Briefly, each study was a prospective,
single-blind, controlled clinical trial in which patients were
randomized to receive either EES (manufactured as Xience V by
Abbott Vascular, Santa Clara, California, and also distrib-
uted as PROMUS by Boston Scientific) or PES (Taxus
Express2, or Taxus Liberté,
Boston Scientific). SPIRIT II
enrolled 300 patients with up to
2 de novo native coronary le-
sions. SPIRIT III enrolled 1,002
patients, with inclusion criteria
similar to the SPIRT II trial.
SPIRIT IV enrolled 3,687 pa-
tients with up to 3 de novo
native coronary artery lesions.
Even though patients with un-
stable angina were enrolled, the
SPIRIT trials excluded many
high-risk patients, including
those with acute or recent myo-
cardial infarction (MI) or visible
thrombus. The COMPARE
trial enrolled 1,800 unselected
patients with no exclusion crite-
ria based on symptoms or lesion
types. Patients with ST-segment
elevation myocardial infarction
(STEMI) and non-STEMI were actively recruited in
COMPARE. Clinical endpoints in all trials were adjudi-
cated by a clinical events committee blinded to stent
assignment.
For the current pooled analysis, the clinical endpoints of
all-cause and cardiac death, MI, ischemia-driven target
lesion revascularization (ID-TLR), and their composites at
consultant for Boston Scientific and Abbott Vascular; has received travel expenses from
Abbott Vascular; has received lecture honoraria from Cordis; and has received payment
for development of educational presentations from Blue Medical. Dr. Kereiakes has served
on the scientific advisory boards for Abbott Vascular and Boston Scientific. Dr. Stone has
served as a consultant to Boston Scientific, Abbott Vascular, Medtronic, Eli Lilly, Merck
& Co. Inc., AstraZeneca, and BMS/Sanofi. All other authors have reported that they
have no relationships relevant to the contents of this paper to disclose.
Abbreviations
and Acronyms
ACS  acute coronary
syndrome(s)
CAD  coronary artery
disease
CI  confidence interval
DES  drug-eluting stent(s)
EES  everolimus-eluting
stent(s)
HR  hazard ratio
ID-TLR  ischemia-driven
target lesion
revascularization
MI  myocardial infarction
PES  paclitaxel-eluting
stent(s)
STEMI  ST-segment
elevation myocardial
infarctionManuscript received January 31, 2011; revised m
accepted June 14, 2011.anuscript received June 1, 2011,
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11062 years were compared by the randomized treatment arms
and stratified by clinical presentation: ACS (including
unstable angina, non–STEMI, and STEMI), and stable
CAD. Stent thrombosis was determined using the Aca-
demic Research Consortium definite or probable definition
(18) and was subclassified as early (30 days), late (30 days
to 1 year), and very late (1 to 2 years).
Statistical analysis. All analyses were performed according
to intention-to-treat. Binary variables are summarized as
counts and percentages and were compared using chi-square
or the Fisher exact test, as appropriate. Continuous variables
are summarized as mean  SD and were compared using t
tests. Two-year outcomes are displayed as time-to-event
event curves, summarized as Kaplan-Meier estimates, and
compared using log-rank tests and hazard ratios. Landmark
analysis was used to determine the rates of early, late, and
very late stent thrombosis. Cox proportional hazards models
with forward stepwise selection were used to adjust for
differences in baseline characteristics. A combined odds
ratio (95% confidence interval [CI]) for the 2-year compos-
ite rates of cardiac death, MI, or ID-TLR was calculated in
the ACS and stable CAD cohorts using a fixed-effects
meta-analysis (inverse-variance weighted). Heterogeneity
was tested with Cochran Q via a chi-square test. All
statistical tests were 2-tailed. A p value of 0.05 was used for
statistical significance.
Results
The pooled patient-level analysis of the SPIRIT II, SPIRIT
III, SPIRIT IV, and COMPARE trials included 6,789
patients, among whom ACS status was known in 6,785. A
total of 2,381 (35%) patients presented with ACS, of whom
1,393 (59%) were randomized to EES and 988 (41%) to
PES. Among 4,404 (65%) patients that presented with
stable CAD, 2,854 (65%) received EES and 1,550 (35%)
received PES. Tests of interactions between source trial and
stent type on 2-year clinical outcomes were all nonsignifi-
Table 1. Characteristics of the Included Studies
SPIRIT II
Number randomized 300
Geography Multicenter, non-U.S.
Stent platform
EES Xience V
PES Taxus Express2
Patients with ACS, % 28.3
Patients with diabetes, % 23.1
Reference vessel diameter, mm, mean  SD 2.73 0.54
Lesion length, mm, mean  SD 13.04 5.90
Planned angiographic follow-up, months 6 and 24
ACS acute coronary syndrome(s); EES everolimus-eluting stent(s); PES paclitaxel-eluting stecant (p  0.58, 0.83, and 0.32 for death; composite cardiacdeath, MI, or ID-TLR; and definite or probable stent
thrombosis, respectively), justifying pooling of the 4 studies.
Outcomes in patients with ACS versus stable CAD. Com-
ared with patients with stable CAD, patients with ACS
ere younger (62.4  11.2 years vs. 63.6  10.3 years) and
ad lower rates of diabetes (24.6% vs. 29.1%), hypertension
59.7% vs. 73.4%), and hyperlipidemia (60.3% vs. 73.3%),
ut a higher rate of smoking (32.9% vs. 20.7%) (p 0.0001
for all). Patients with ACS also had higher rate of TIMI
(Thrombolysis In Myocardial Infarction) flow grade 0/1 at
baseline (14.8% vs. 4.2%), and coronary thrombus (18.9%
vs. 2.5%), and they were treated with longer stents (35.9 
25.6 mm vs. 31.2  21.7 mm) (p  0.0001 for all). At 2
ears, patients with ACS compared with those with stable
AD had higher rates of death (3.2% vs. 2.4%, hazard ratio
HR]: 1.37 [95% CI: 1.02 to 1.85], p 0.04), MI (4.9% vs.
3.4%, HR: 1.45 [95% CI: 1.14 to 1.85], p  0.02), and
cademic Research Consortium definite or probable stent
hrombosis (1.6% vs. 1.1%, HR: 1.54 [95% CI: 1.00 to
.38], p  0.05), with similar rates of ID-TLR (5.4% vs.
.9%, HR: 1.06 [95% CI: 0.85 to 1.33], p  0.56).
Baseline characteristics according to stent type. As shown in
able 2, among patients with ACS, those randomized to
ES versus PES were less frequently men and were more
ikely to have hyperlipidemia and prior MI. Patients ran-
omized to EES were also less likely to have moderate or
evere calcification or thrombus, and they had slightly
horter lesions but in smaller vessels. In the stable CAD
ohort, patients treated with EES versus PES had a higher
ate of hypertension and lower rates of total occlusions and
alcified vessels, with a slightly larger reference vessel
iameter. The rates of aspirin and thienopyridine use with
oth stents at discharge and at the 1-year landmark were not
ignificantly different in patients with ACS and stable
AD.
Clinical outcomes according to randomized stent type.
Treatment with EES versus PES resulted in significantly
SPIRIT III SPIRIT IV COMPARE
1,002 3,687 1,800
lticenter, U.S. Multicenter, U.S. Single-center, the Netherlands
Xience V Xience V Xience V
xus Express2 Taxus Express2 Taxus Liberté
20.5 27.6 59.8
29.0 32.2 18.1
2.76 0.46 2.68 0.50 2.63 0.60
4.71 5.62 14.70 6.65 22.42 17.41
8 None NoneMu
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1107and stable CAD groups. In the ACS cohort (Table 3, Fig. 1),
patients treated with EES rather than PES had a lower rate
of ID-TLR at 30 days, and lower rates of MI (especially
Q-wave MI), death or MI, and ID-TLR at 2 years.
Similarly, in the stable CAD cohort (Table 4, Fig. 2),
treatment with EES rather than PES resulted in signifi-
cantly lower rates of MI, death or MI, and ischemic TLR
Table 2. Baseline Characteristics and Antiplatelet Ag
AC
Variable
EES
(n  1,393)
P
(n 
Demographics
Age, yrs 62.1 11.2 62.7
Male 65.5% (912) 71.6
Diabetes mellitus 26.0% (362) 22.7
Insulin-treated 6.5% (91) 6.7
Current smoking 33.3% (457) 32.4
Hypertension 61.2% (852) 57.7
Hyperlipidemia 63.1% (869) 56.4
Prior CABG 6.7% (93) 5.6
Prior MI 22.9% (312) 18.6
Prior PCI 13.3% (184) 12.3
Presenting diagnosis
Stable angina 0.0% (0) 0.0
Unstable angina 68.8% (959) 56.6
Non–STEMI 13.9% (194) 22.0
STEMI 17.2% (240) 21.5
Target lesion characteristics
RCA 34.8% (644) 35.4
LAD 39.0% (720) 37.4
LCX 25.7% (475) 26.3
Left main 0.5% (9) 0.8
SVG 1.0% (19) 1.1
Total occlusion 4.1% (76) 5.5
Moderate or severe calciﬁcation 16.2% (298) 19.7
Thrombus 16.3% (300) 22.6
Lesion length, mm 17.0 11.1 18.4
RVD, mm 2.66 0.52 2.72
MLD, mm 0.76 0.44 0.81
Diameter stenosis, % 71.9 15.8 70.9
Antiplatelet therapy
Discharge
Aspirin 96.3% (1,333) 96.9
Thienopyridine 99.1% (1,372) 99.6
1 yr
Aspirin 93.7% (1,283) 92.7
Thienopyridine 82.0% (1,122) 80.0
Values are mean SD or % (n).
CABG  coronary artery bypass graft; CAD  coronary artery dise
coronary artery; MI  myocardial infarction; MLD  minimal luminal
artery; RVD reference vessel diameter; STEMI ST-segment elevatio
in Table 1.at 30 days and 2 years. The odds ratio for the compositeof cardiac death, MI, or ID-TLR at 2 years for EES
versus PES by the individual source trial and combined
meta-analysis is shown in Figure 3. Significant heteroge-
neity was not present among the individual trial
outcomes.
Multivariable analysis was performed to adjust for differ-
ences in baseline patient and lesion characteristics. Adjusted
se
Stable CAD
p Value
EES
(n  2,854)
PES
(n  1,550) p Value
0.19 63.5 10.2 63.7 10.4 0.50
) 0.002 70.0% (1,999) 68.3% (1,058) 0.23
) 0.07 29.0% (826) 29.5% (456) 0.75
0.87 7.7% (219) 7.6% (118) 1.00
) 0.66 20.9% (585) 20.3% (308) 0.69
) 0.10 74.5% (2,124) 71.4% (1,106) 0.03
) 0.001 74.1% (2,080) 71.9% (1,104) 0.11
0.30 7.5% (213) 6.3% (98) 0.18
) 0.01 19.1% (535) 19.2% (294) 0.97
) 0.49 15.1% (426) 14.9% (228) 0.86
— 80.5% (2,254) 82.2 (1,248) 0.18
) 0.0001 0.0% (0) 0.0% (0) —
) 0.0001 0.0% (0) 0.0% (0) —
) 0.01 0.0% (0) 0.0% (0) —
) 0.73 33.8% (1,221) 32.7% (664) 0.41
) 0.39 41.2% (1,489) 41.1% (834) 0.93
) 0.71 24.6% (889) 25.7% (521) 0.39
0.26 0.4% (13) 0.5% (11) 0.39
1.00 0.2% (8) 0.5% (10) 0.09
0.09 0.9% (33) 2.2% (45) 0.0001
) 0.01 13.3% (477) 16.7% (337) 0.0006
) 0.0001 2.6% (92) 2.4% (49) 0.79
0.01 15.5 8.6 15.9 9.7 0.14
0.005 2.69 0.51 2.66 0.52 0.04
0.003 0.82 0.41 0.83 0.42 0.25
0.11 69.5 14.0 68.7 14.6 0.06
) 0.42 97.8% (2,790) 96.8% (1,501) 0.07
) 0.21 99.4% (2,836) 99.2% (1,538) 0.57
) 0.36 93.7% (2,646) 92.6% (1,423) 0.20
) 0.26 81.6% (2,306) 82.0% (1,260) 0.77
D  left anterior descending coronary artery; LCX  left circumflex
er; PCI  percutaneous coronary intervention; RCA  right coronary
ardial infarction; SVG saphenous vein graft; other abbreviations asent U
S
ES
988)
 10.9
% (707
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% (316
% (569
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1108both cohorts (Table 5). No significant interactions in the
relative treatment effects were found between the random-
ized stent type and ACS versus stable CAD presentation for
the 2-year rates of death; death or MI; and death, MI, or
ID-TLR (p  0.73, 0.52, and 0.12, respectively).
Stent thrombosis. Randomization to EES versus PES re-
ulted in a substantial reduction of stent thrombosis both in
atients with ACS and stable CAD (Tables 2 and 3). The
-year rates of stent thrombosis after EES were similar
mong patients with stable CAD and ACS (0.7% vs. 0.7%,
espectively, p  0.72). Conversely, the 2-year rates of stent
hrombosis in patients treated with PES occurred in 1.8%
nd 2.9% of patients with stable CAD and ACS, respec-
ively (p  0.09). The 2-year rates of definite or probable
stent thrombosis in patients with stable CAD, unstable
angina, non-STEMI, and STEMI treated with EES were
0.7%, 0.4%, 1.6%, and 1.3%, respectively (p for trend 
0.19), compared with 1.8%, 1.5%, 6.1%, and 3.4%, respec-
Table 3. Clinical Outcomes in Patients Presenting W
EES
30-day outcomes
Death, all-cause 0.6% (8
Cardiac death 0.5% (7
Noncardiac death 0.1% (1
MI, all 1.7% (2
Q-wave MI 0.3% (4
Non–Q-wave MI 1.4% (1
ID-TLR 0.3% (4
Death or MI 2.2% (3
Cardiac death or MI 2.1% (2
Death, MI, or ID-TLR 2.4% (3
Cardiac death, MI, or ID-TLR 2.3% (3
2-yr outcomes
Death, all-cause 2.8% (3
Cardiac death 1.4% (1
Noncardiac death 1.5% (2
MI, all 4.0% (5
Q-wave MI 0.4% (5
Non–Q-wave MI 3.6% (4
ID-TLR 4.7% (6
Death or MI 6.6% (9
Cardiac death or MI 5.2% (7
Death, MI, or ID-TLR 10.1% (1
Cardiac death, MI, or ID-TLR 8.7% (1
Stent thrombosis
ARC deﬁnite 0.4% (6
ARC probable 0.3% (4
ARC deﬁnite or probable 0.7% (1
Cardiac death, MI, or stent thrombosis 5.3% (7
Events rates are summarized as Kaplan-Meier % (n of events).
ARCAcademic Research Consortium; CI confidence interval; HR
applicable; other abbreviations as in Tables 1 and 2.tively (p for trend  0.0004) in patients treated with PESFig. 4). Treatment with EES rather than PES was associ-
ted with lower rates of stent thrombosis in the early, late,
nd very late periods (Fig. 5), in both the ACS and stable
AD cohorts.
iscussion
With more than 13,000 patient-years of follow-up, the
present patient-level pooled analysis is the largest random-
ized comparison between any 2 DES to date. The main
findings of the current analysis are: 1) the prognosis of
patients with ACS in the entire cohort was worse than those
with stable CAD, with higher 2-year rates of death, MI,
and stent thrombosis; 2) treatment with EES versus PES
markedly reduced the 2-year rates of adverse clinical events
in both ACS and stable CAD patients; 3) treatment with
EES also resulted in a substantial decrease in the rate of
ACS According to Randomized Stent
PES HR (95% CI) p Value
0.5% (5) 1.14 (0.37–3.47) 0.82
0.5% (5) 0.99 (0.32–3.13) 0.99
0.0% (0) N/A 0.40
2.4% (24) 0.68 (0.38–1.20) 0.18
0.6% (6) 0.47 (0.13–1.67) 0.23
1.8% (18) 0.75 (0.39–1.43) 0.38
1.2% (12) 0.24 (0.08–0.73) 0.006
2.8% (28) 0.76 (0.45–1.27) 0.29
2.8% (28) 0.73 (0.44–1.23) 0.24
2.9% (29) 0.81 (0.49–1.33) 0.40
2.9% (29) 0.78 (0.47–1.29) 0.34
3.6% (35) 0.79 (0.50–1.25) 0.31
1.9% (18) 0.75 (0.39–1.43) 0.38
1.8% (17) 0.84 (0.44–1.59) 0.58
6.2% (60) 0.63 (0.44–0.91) 0.01
1.7% (15) 0.23 (0.08–0.64) 0.002
4.8% (46) 0.75 (0.50–1.12) 0.16
6.2% (60) 0.69 (0.48–0.99) 0.04
9.3% (91) 0.70 (0.52–0.94) 0.02
7.7% (75) 0.66 (0.48–0.92) 0.01
12.6% (123) 0.77 (0.60–0.98) 0.04
11.0% (107) 0.76 (0.58–0.98) 0.04
2.2% (21) 0.20 (0.08–0.50) 0.01
0.7% (7) 0.41 (0.12–1.39) 0.0008
2.9% (28) 0.25 (0.12–0.52) 0.0002
7.7% (75) 0.67 (0.49–0.93) 0.02
ratio; ID-TLR ischemia-driven target lesion revascularization; NAnotith an
)
)
)
3)
)
9)
)
0)
9)
3)
2)
9)
9)
0)
4)
)
9)
0)
1)
1)
36)
16)
)
)
0)
2)
hazardstent thrombosis, with reductions apparent throughout the
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11092-year follow-up period in both patients with and without
ACS.
Patients presenting with ACS most often have plaque
rupture of a thin-cap fibroatheroma, which contains a large
lipid core with thin fibrous cap, paucity of smooth muscle
cells, and abundance of inflammatory cells (19). In contrast,
atherosclerotic plaques in patients presenting with stable
angina tend to have a thick fibrous cap rich in smooth
muscle cells with a small or absent necrotic core (patholog-
ical intimal thickening). Different DES may have a differ-
ential impact on outcome in these 2 distinct clinical syn-
dromes (20). Even though DES substantially reduce
neointimal hyperplasia in stable plaques by inhibiting cell
proliferation, migration, and extracellular matrix produc-
Figure 1. Time-to-Event Event Curves for Patients Presenting With ACS Ra
Two-year cumulative event curves for cardiac death (A), myocardial infarction (MI
cardiac death, MI, or ID-TLR (D). ACS  acute coronary syndromes; CI  conﬁde
eluting stent(s).tion, this mechanism may in theory be harmful in thesetting of plaque rupture and a prothrombotic milieu,
resulting in poor arterial healing and an increased risk for
stent thrombosis (21). Indeed, the safety of the first-
generation DES in ACS patients has been questioned
(6 – 8). DES were not originally tested in patients with
acute thrombotic syndromes in the trials leading to their
regulatory approval, and thus are not indicated in ACS
(22). Although accumulating data have demonstrated
that the use of DES in ACS patients (including STEMI)
is safe and reduces restenosis (3–5,23), no randomized
clinical trials have compared different types of DES in
these high-risk patients. Specifically, whether DES
which are more potent at inhibiting neointimal growth
than those which are less potent are favored in this setting
ized to EES Versus PES
chemia-driven target lesion revascularization (ID-TLR) (C), and the composite of
terval; EES  everolimus-eluting stent(s); HR  hazard ratio; PES  paclitaxel-ndom
) (B), is
nce inis unknown.
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1110The present large-scale pooled analysis afforded the
opportunity to examine the outcomes with EES and PES in
patients with ACS. Pooling the 4 randomized trials afforded
additional power to examine subgroup outcomes, which was
not otherwise possible within any single study. The results
of the current study demonstrate for the first time that EES
are more safe and effective than PES both in patients with
ACS as well as stable CAD, with reductions in the 2-year
rates of MI and ID-TLR. Moreover, treatment with EES
versus PES resulted in a marked reduction in stent throm-
bosis in both patients with and without ACS. Indeed, the
greatest absolute reductions in stent thrombosis with EES
versus PES were observed in patients with non-STEMI and
STEMI.
In the current analysis, treatment with EES was superior
to PES throughout 2 years of follow-up in both the ACS
and stable CAD cohorts, with the hazard curves continu-
ing to diverge over time. At 30 days, the differences in the
rates of MI and ID-TLR may be attributed to the higher
Table 4. Clinical Outcomes in Patients Presenting W
EES
30-day outcomes
Death, all-cause 0.0% (1)
Cardiac 0.0% (0)
Noncardiac 0.0% (1)
MI, all 1.4% (39)
Q-wave MI 0.1% (2)
Non–Q-wave MI 1.3% (37)
ID-TLR 0.4% (11)
Death or MI 1.4% (39)
Cardiac death or MI 1.4% (39)
Death, MI, or ID-TLR 1.4% (41)
Cardiac death, MI, or ID-TLR 1.4% (41)
2-yr outcomes
Death, all-cause 2.3% (62)
Cardiac 1.1% (30)
Noncardiac 1.2% (32)
MI, all 2.4% (68)
Q-wave MI 0.1% (4)
Non–Q-wave MI 2.3% (64)
ID-TLR 3.9% (107
Death or MI 4.5% (124
Cardiac death or MI 3.4% (95)
Death, MI, or ID-TLR 7.7% (213
Cardiac death, MI, or ID-TLR 6.6% (184
Stent thrombosis
ARC deﬁnite 0.5% (14)
ARC probable 0.1% (4)
ARC deﬁnite or probable 0.7% (18)
Cardiac death, MI, or stent thrombosis 3.5% (98)
Events rates are summarized as Kaplan-Meier % (n of events).
Abbreviations as in Tables 1, 2, and 3.rate of early stent thrombosis and periprocedural myone-crosis with PES, the latter most likely a result of
side-branch compromise (24). At 2 years, superiority of
EES can be attributed to reductions in MI, stent throm-
bosis, and restenosis. Importantly, there were no signif-
icant interactions between stent type and clinical syn-
drome on 2-year outcomes, signifying that the relative
benefits of EES are consistent in both high-risk patients
with ACS and lower-risk patients with stable CAD
(although the absolute benefits may be greater in the
higher risk ACS cohort).
As clinical syndrome acuity increased from stable CAD
to unstable angina to non-STEMI to STEMI, the risk of
stent thrombosis significantly increased with PES but not
EES. EES thus appears to mitigate the local prothrombotic
effect of ACS as a risk factor for early and late stent
thrombosis. The number of patients needed to treat with
EES versus PES to prevent 1 event of definite or probable
stent thrombosis was 45 in the ACS cohort and 91 in the
stable angina cohort. Further studies are required to com-
able CAD According to Randomized Stent
PES HR (95% CI) p Value
0.1% (2) 0.27 (0.02–2.99) 0.25
0.1% (2) — 0.06
0.0% (0) — 0.46
2.6% (41) 0.51 (0.33–0.80) 0.002
0.3% (4) 0.27 (0.05–1.48) 0.11
2.5% (38) 0.53 (0.34–0.83) 0.005
1.0% (16) 0.37 (0.17–0.80) 0.009
2.7% (42) 0.50 (0.32–0.78) 0.002
2.7% (42) 0.50 (0.32–0.78) 0.002
3.2% (49) 0.45 (0.30–0.68) 0.0001
3.2% (49) 0.45 (0.30–0.68) 0.0001
2.6% (38) 0.88 (0.58–1.31) 0.52
1.3% (19) 0.85 (0.48–1.51) 0.57
1.3% (19) 0.90 (0.51–1.59) 0.72
5.1% (77) 0.47 (0.34–0.66) 0.0001
0.9% (13) 0.17 (0.05–0.51) 0.0003
4.4% (67) 0.51 (0.36–0.72) 0.0001
6.9% (102) 0.55 (0.42–0.73) 0.0001
7.1% (107) 0.62 (0.48–0.80) 0.0002
5.8% (88) 0.58 (0.43–0.77) 0.0002
12.4% (185) 0.60 (0.49–0.73) 0.0001
11.1% (166) 0.58 (0.47–0.72) 0.0001
1.2% (18) 0.42 (0.21–0.84) 0.01
0.8% (12) 0.18 (0.06–0.56) 0.0008
1.8% (28) 0.34 (0.19–0.62) 0.0002
6.0% (90) 0.58 (0.44–0.77) 0.0002ith St
)
)
)
)pletely understand the apparent disconnect between the
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1111potent inhibition of neointimal hyperplasia with EES and
its protection from stent thrombosis. Theoretically, different
mechanisms of action of the drugs or the polymers in terms
of inhibition of neointimal proliferation and vascular heal-
ing may in part explain the disparity in the risk for stent
thrombosis in different clinical syndromes with the 2 stents
(10). Animal models have shown that the EES has more
rapid and complete re-endothelialization than PES do (10).
Moreover, the biocompatible fluorocopolymer used by the
EES has been shown to be resistant to platelet and
thrombus deposition in numerous blood-contact applica-
tions (25,26).
In the present series of trials, EES was compared with
PES. Whether EES would demonstrate the same safety and
efficacy profile if compared with sirolimus-eluting stents,
Figure 2. Time-to-Event Event Curves for Patients Presenting With Stable C
Two-year cumulative event curves for cardiac death (A), MI (B), ID-TLR (C), an
disease; other abbreviations as in Figure 1.which have greater antirestenotic efficacy than PES do (27), ohas not yet been tested in adequately powered randomized
trials. In the recently published BASKET–PROVE (Basal
Stent Kosten-Effektivitats Trial–Prospective Validation Ex-
amination) (28), no significant differences with regard to
death, MI, TLR, and stent thrombosis rates were found
between EES and sirolimus-eluting stents in patients with
large coronary arteries (those requiring 3.0- to 4.0-mm
stents).
Study limitations. This study is limited by its post-hoc
ature, and the results should thus be considered
ypothesis-generating. The SPIRIT trials enrolled patients
ith unstable angina, but excluded patients with acute or
ecent MI. In contrast, the COMPARE trial actively
nrolled patients with non-STEMI and STEMI. Random-
zation was not stratified by clinical syndrome acuity in any
andomized to EES Versus PES
composite of cardiac death, MI, or ID-TLR (D). CAD  coronary arteryAD R
d thef the enrolled studies, resulting in some differences in
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1112Figure 3. Odds Ratio Forest Plot (Fixed-Effects Model)
Pooled odds ratio for the composite of cardiac death, MI, or ID-TLR in patients treated with EES compared with PES in the ACS cohort (A) and the stable CAD
cohort (B). The p values for heterogeneity across studies was 0.35 and 0.65 for the ACS and stable CAD cohorts, respectively. COMPARE  A Trial of Everolimus-Eluting
Stents and Paclitaxel-Eluting Stents for Coronary Revascularization in Daily Practice; SPIRIT II  A Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent
System in the Treatment of Patients With de Novo Native Coronary Artery Lesions; SPIRIT III  A Clinical Evaluation of the Investigational Device XIENCE V Everolimus
Eluting Coronary Stent System (EECSS) in the Treatment of Subjects With de Novo Native Coronary Artery Lesions; SPIRIT IV  A Clinical Evaluation of the XIENCE V
Everolimus Eluting Coronary Stent System in the Treatment of Subjects With de Novo Native Coronary Artery Lesions; other abbreviations as in Figures 1 and 2.
TIMI Thrombolysis In Myocardial Infarction; other abbreviations as in Tables 1, 2, and 3.
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1113Figure 4. Stent Thrombosis Rates at 2 Years According to Clinical Syndrome Acuity in Patients Randomized to EES Versus PESARC  Academic ResTable 5. Two-Year Adjusted HR for EES Compared With PES According to Clinical Syndrome Acuity
Variable n Events Adjusted HR (95% CI) p Value
ACS patients
Death, all cause 1,996 54 0.80 (0.47–1.36) 0.41
Cardiac 2,371 37 0.79 (0.41–1.52) 0.49
Death or MI 2,336 180 0.69 (0.51–0.93) 0.01
Cardiac death or MI 1,996 103 0.68 (0.46–1.00) 0.05
Death, MI, or ID-TLR 2,359 258 0.76 (0.60–0.97) 0.03
Cardiac death, MI, or ID-TLR 2,084 182 0.76 (0.57–1.01) 0.06
Stent thrombosis
ARC deﬁnite 2,343 27 0.18 (0.07–0.45) 0.0003
ARC deﬁnite or probable 2,323 38 0.24 (0.11–0.49) 0.0001
Stable CAD patients
Death, all cause 4,252 96 0.86 (0.57–1.29) 0.46
Cardiac 4,399 49 0.83 (0.46–1.47) 0.51
Death or MI 4,017 205 0.63 (0.48–0.83) 0.0009
Cardiac death or MI 3,967 159 0.60 (0.44–0.82) 0.002
Death, MI, or ID-TLR 4,082 365 0.61 (0.50–0.75) 0.0001
Cardiac death, MI, or ID-TLR 4,006 316 0.59 (0.47–0.73) 0.0001
Stent thrombosis
ARC deﬁnite 4,190 32 0.42 (0.21–0.84) 0.01
ARC deﬁnite or probable 4,012 41 0.36 (0.19–0.68) 0.001
The Cox model included the following covariates: stent type, age, sex, any diabetes, insulin-dependent diabetes, current smoker, hypertension,
hyperlipidemia, prior CABG, prior MI, prior PCI, vessel-treated, calcification, total occlusion, thrombus, baseline TIMI flow grade 0/1, lesion length,
baseline reference vessel diameter, baseline minimal luminal diameter.earch Consortium; STEMI  ST-segment elevation myocardial infarction; other abbreviations as in Figures 1 and 2.
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1114Figure 5. Landmark Analysis of Early, Late, and Very Late Stent Thrombosis According to Randomized Stent Type
Time-to-event curves with landmark analysis at 30 days and 1 year for deﬁnite or probable stent thrombosis in patients presenting with ACS (A) and stable CAD (B).
Abbreviations as in Figures 1 and 2.
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1115baseline characteristics between the EES and PES groups in
the ACS and stable CAD cohorts. Other differences be-
tween the trials were present in terms of inclusion and
exclusion criteria, different randomization ratio (2:1 or 3:1
in the SPIRIT trials and 1:1 in the COMPARE trial), and
the stent used in the PES arm (Taxus Express2 in the
SPIRIT trials and Taxus Liberté in COMPARE). How-
ever, the multivariable adjusted hazard ratios were very
similar to unadjusted hazard ratios in both the ACS and
stable CAD cohorts. Finally, the operators were not blinded
to stent type implanted; however, patients, caregivers, and
study personnel outside the catheterization laboratory, as
well as the Clinical Events Committee, were blinded to the
stent type deployed.
Conclusions
In this large-scale, patient-level pooled analysis from 4 pro-
spective, randomized trials, the use of EES compared with
PES resulted in superior safety and efficacy in both patients
with ACS and stable CAD, with substantial reductions ob-
served in the 2-year rates of death or MI, stent thrombosis, and
ID-TLR independent of clinical syndrome acuity.
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